Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Charles R. Drew University of Medicine and Science, Los Angeles, California, United States
Contact: Study coordinator (Piwen Wang, PhD) · piwenwang@cdrewu.edu · 323-563-4999

Study leads

Piwen Wang, PhD
Principal Investigator
Charles Drew University of Medicine and Science

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Metastatic Castration-resistant Prostate Cancer

Abroad (travel likely)RecruitingPHASE3

Orange, United States · Miami, United States

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Metastatic Castration-Resistant Prostate Cancer

Abroad (travel likely)RecruitingPHASE3

Chandler, United States · Gilbert, United States

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Advanced Solid Tumor · Diffuse Large B Cell Lymphoma · Lymphoma, T-Cell

Abroad (travel likely)RecruitingPHASE1, PHASE2

Tampa, United States · Atlanta, United States

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Aarau, Switzerland · Baden, Switzerland